Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
Regorafenib Alone or in Combination With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 90
- Registration Number
- NCT05963490
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 340
- Registration Number
- NCT05954078
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 203
- Registration Number
- NCT05954442
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-07-19
- Last Posted Date
- 2023-07-19
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 69
- Registration Number
- NCT05953168
- Locations
- 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China
Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 265
- Registration Number
- NCT05949541
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable CRLM
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-07-17
- Last Posted Date
- 2023-07-17
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 250
- Registration Number
- NCT05948072
- Locations
- 🇨🇳
Zhongshan hosptial, Fudan University, Shanghai, China
A Study of HRXG-K-1939 and Adebrelimab in Patients With Advanced Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-07-12
- Last Posted Date
- 2023-07-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT05942378
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
LRAMPS Versus LDP in Selected Early-stage Left-sided Pancreatic Cancer
Not Applicable
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-07-11
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 160
- Registration Number
- NCT05939063
- Locations
- 🇨🇳
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE-Trop2)
Phase 1
Not yet recruiting
- Conditions
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 125
- Registration Number
- NCT05928780
A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-06-29
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 88
- Registration Number
- NCT05924256
- Locations
- 🇨🇳
Dongmei Ji, Shanghai, China
© Copyright 2024. All Rights Reserved by MedPath